2020
Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults
Zeitouni M, Nanna MG, Sun JL, Chiswell K, Peterson ED, Navar AM. Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. Journal Of The American College Of Cardiology 2020, 76: 653-664. PMID: 32762899, PMCID: PMC7444655, DOI: 10.1016/j.jacc.2020.06.030.Peer-Reviewed Original ResearchConceptsLipid-Lowering TherapyYears of agePremature myocardial infarctionIntensive lipid-lowering therapyHigh-risk criteriaMyocardial infarctionYoung adultsYounger patientsHigh low-density lipoprotein cholesterolAHA/ACC guidelinesMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolDuke University Medical CenterACC/AHAAdverse cardiovascular eventsRecurrent myocardial infarctionMost young patientsReductase inhibitor therapyFirst myocardial infarctionAmerican Heart AssociationUniversity Medical CenterOlder age groupsCause deathCholesterol guidelinesStatin candidatesImplications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography
Daubert MA, Sivak J, Dunning A, Douglas PS, Coyne B, Wang TY, Mark DB, Velazquez EJ. Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. JAMA Internal Medicine 2020, 180: 494-502. PMID: 31985749, PMCID: PMC6990669, DOI: 10.1001/jamainternmed.2019.6958.Peer-Reviewed Original ResearchConceptsNormal stress echocardiographyComposite end pointStress echoExercise electrocardiographyStress echocardiographyMyocardial infarctionDownstream testingEnd pointDuke University Medical CenterExercise stress echoNegative exercise ECGStress ECG findingsAdverse cardiac eventsIncremental prognostic valueObservational cohort studyAdverse clinical eventsCoronary artery diseaseIndividual adverse eventsPopulation of patientsUniversity Medical CenterImaging resultsCoronary revascularizationAdverse eventsCardiac eventsCohort study
2019
Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction
DeVore AD, Yow E, Krucoff MW, Sherwood MW, Shaw LK, Chiswell K, O'Connor CM, Ohman EM, Velazquez EJ. Percutaneous coronary intervention outcomes in patients with stable coronary disease and left ventricular systolic dysfunction. ESC Heart Failure 2019, 6: 1233-1242. PMID: 31560171, PMCID: PMC6989282, DOI: 10.1002/ehf2.12510.Peer-Reviewed Original ResearchConceptsStable coronary artery diseasePercutaneous coronary interventionCoronary artery diseaseVentricular systolic dysfunctionSevere left ventricular systolic dysfunctionLeft ventricular systolic dysfunctionSystolic dysfunctionMedical therapyCardiovascular hospitalizationAddition of PCICanadian Cardiovascular Society class IIIImpact of PCIPercutaneous coronary intervention outcomesDuke University Medical CenterComposite of mortalityPropensity-matched cohortStable coronary diseaseAcute coronary syndromeHigh-risk patientsLong-term mortalityVentricular ejection fractionCox proportional hazardsUniversity Medical CenterCause mortalityCoronary syndromeGlobal Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus
Alenezi F, Bloomfield GS, Okeke NL, Velagapudi P, Abudaqa L, Ijioma N, Dunning A, Alajmi H, Clement ME, Shah SH, Naggie S, Velazquez EJ. Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. The American Journal Of Cardiology 2019, 124: 966-971. PMID: 31371060, PMCID: PMC6887515, DOI: 10.1016/j.amjcard.2019.06.013.Peer-Reviewed Original ResearchConceptsLV ejection fractionHIV-1 RNA viral loadNormal LV ejection fractionRNA viral loadHuman immunodeficiency virusViral loadImmunodeficiency virusImmune statusGlobal longitudinal strain analysisNadir CD4 cell countPreclinical left ventricular dysfunctionDuke University Medical CenterCD4 cell countPlasma HIV RNALeft ventricular dysfunctionGlobal longitudinal strainCells/Longitudinal strain analysisUniversity Medical CenterCD4 cell count dataAbnormal GLSNadir CD4CD4 countHIV RNAVentricular dysfunction
2018
Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation
Alenezi F, Fudim M, Rymer J, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, Velazquez E, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2018, 123: 813-819. PMID: 30598241, DOI: 10.1016/j.amjcard.2018.11.038.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLV ejection fractionAortic stenosisValve implantationEjection fractionLV massCardiac hemodynamicsBaseline LV ejection fractionLeft ventricle mass indexPost-TAVI paravalvular leakLV global longitudinal strainDuke University Medical CenterBaseline LV massLV mass regressionSevere aortic stenosisVentricle mass indexGlobal longitudinal strainTreatment of patientsUniversity Medical CenterGreat clinical successTAVI patientsReverse remodelingTransthoracic echocardiographyMedian ageDeterminants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort
Okeke NL, Alenezi F, Bloomfield GS, Dunning A, Clement ME, Shah SH, Naggie S, Velazquez EJ. Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. Journal Of Cardiac Failure 2018, 24: 496-503. PMID: 29964194, PMCID: PMC6231907, DOI: 10.1016/j.cardfail.2018.06.003.Peer-Reviewed Original ResearchConceptsLeft ventricular hypertrophyDiastolic dysfunctionTransthoracic echocardiogramVentricular hypertrophyHuman immunodeficiency virus-infected personsDuke University Medical CenterDefinite diastolic dysfunctionHIV Clinical CohortStructural myocardial abnormalitiesVirus-infected personsHuman immunodeficiency virusCells/University Medical CenterCD4 nadirsCD4 countViral suppressionPrimary outcomeImmune suppressionImmunodeficiency virusMyocardial abnormalitiesClinical cohortMedical CenterHigh riskImmune functionInfected persons
2017
Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Shammas R, Cho E, Glener A, Poveromo L, Mundy L, Greenup R, Blackwell K, Hollenbeck S. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. Journal Of The American College Of Surgeons 2017, 225: 731-739.e1. PMID: 28985927, DOI: 10.1016/j.jamcollsurg.2017.08.023.Peer-Reviewed Original ResearchConceptsPostoperative wound breakdownBreast reconstructionReconstructive complicationsWound breakdownReconstructive operationsPropensity score-matched pairsMastectomy skin flap necrosisDuke University Medical CenterAdministration of trastuzumabPrimary study outcomeSkin flap necrosisLarger tumor sizePost-mastectomy reconstructionBreast reconstruction outcomesOccurrence of hematomaUniversity Medical CenterPertuzumab therapyChemotherapy regimenNeoadjuvant chemotherapyOperative interventionFlap thrombosisTrastuzumab therapySurgical outcomesTumor sizeFlap necrosisLeft ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization
Buggey J, Alenezi F, Yoon HJ, Phelan M, DeVore AD, Khouri MG, Schulte PJ, Velazquez EJ. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Failure 2017, 4: 432-439. PMID: 29154416, PMCID: PMC5695196, DOI: 10.1002/ehf2.12159.Peer-Reviewed Original ResearchConceptsAcute heart failure hospitalizationVentricular global longitudinal strainAbnormal LV-GLSLV-GLSHeart failure hospitalizationGlobal longitudinal strainAcute HFpEFFailure hospitalizationEjection fractionHeart failureLongitudinal strainCox proportional hazards modelDuke University Medical CenterComposite of mortalityMedian LV-GLSWorse LV-GLSChronic heart failureWorse clinical outcomesMyocardial systolic dysfunctionSpeckle-tracking analysisProportional hazards modelUniversity Medical CenterMultivariable adjustmentSystolic dysfunctionBaseline characteristics
2016
Baseline Pulse Pressure, Acute Kidney Injury, and Mortality After Noncardiac Surgery
Oprea AD, Lombard FW, Liu WW, White WD, Karhausen JA, Li YJ, Miller TE, Aronson S, Gan TJ, Fontes ML, Kertai MD. Baseline Pulse Pressure, Acute Kidney Injury, and Mortality After Noncardiac Surgery. Anesthesia & Analgesia 2016, 123: 1480-1489. PMID: 27607474, DOI: 10.1213/ane.0000000000001557.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAcute Kidney InjuryAdultAgedAged, 80 and overArterial PressureChi-Square DistributionFemaleHumansHypertensionIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisNorth CarolinaOdds RatioRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSurgical Procedures, OperativeTime FactorsTreatment OutcomeConceptsPostoperative acute kidney injuryAcute kidney injuryBaseline pulse pressureNoncardiac surgeryPulse pressureKidney injuryIncidence of AKIAdvanced stageBaseline arterial blood pressureMultivariable logistic regression analysisDuke University Medical CenterPreoperative pulse pressurePerioperative risk factorsArterial blood pressureImportant independent predictorLogistic regression analysisUniversity Medical CenterRisk-adjusted modelsCardiovascular outcomesAdult patientsBlood pressureCardiac surgeryIndependent predictorsRisk factorsMedical Center
2015
Use of outcome measures in pulmonary hypertension clinical trials
Parikh KS, Rajagopal S, Arges K, Ahmad T, Sivak J, Kaul P, Shah SH, Tapson V, Velazquez EJ, Douglas PS, Samad Z. Use of outcome measures in pulmonary hypertension clinical trials. American Heart Journal 2015, 170: 419-429.e3. PMID: 26385024, DOI: 10.1016/j.ahj.2015.06.010.Peer-Reviewed Original ResearchConceptsHypertension clinical trialsPulmonary arterial hypertensionPAH trialsClinical practiceInvasive hemodynamicsPrimary endpointClinical trialsOutcome measuresInvasive measuresSurrogate measureDuke University Medical CenterPatient-centered endpointsSecondary outcome measuresClinical treatment trialsMEDLINE/EMBASEUniversity Medical CenterSmall patient populationQuality of lifeContemporary clinical practicePAH therapyPH medicationsArterial hypertensionSerial echocardiographyPatient characteristicsSecondary outcomes
2014
Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease
Holmqvist F, Thomas KL, Broderick S, Ersbøll M, Singh D, Chiswell K, Shaw LK, Hegland DD, Velazquez EJ, Daubert JP. Clinical outcome as a function of the PR-interval—there is virtue in moderation: data from the Duke Databank for cardiovascular disease. EP Europace 2014, 17: 978-985. PMID: 25164430, DOI: 10.1093/europace/euu211.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseHeart diseaseDuke University Medical CenterMajor cardiovascular outcomesMajor cardiovascular eventsNative coronary arteriesUniversity Medical CenterPR interval durationCV eventsCardiovascular eventsCardiovascular outcomesCause mortalityCoronary angiographyDuke DatabankClinical outcomesAtrial fibrillationPoor outcomeCoronary arterySignificant stenosisSinus rhythmCardiovascular diseaseMedical CenterHigh riskPatientsRelevant covariates
2007
Who refuses enrollment in cardiac clinical trials?
Sen Biswas M, Newby LK, Bastian LA, Peterson ED, Sugarman J. Who refuses enrollment in cardiac clinical trials? Clinical Trials 2007, 4: 258-263. PMID: 17715252, DOI: 10.1177/1740774507079434.Peer-Reviewed Original ResearchConceptsClinical trialsAcute settingRefusal rateDuke University Medical CenterNon-white patientsUniversity Medical CenterHigh refusal rateInformed consent formLow refusal rateACUITY trialMean ageSingle institutionMeaningful informed consentMedical CenterSociodemographic characteristicsOlder personsClinical researchInformed consentPatientsTrialsConsent formMain reasons peopleLimited dataYoung personEfficiency of recruitment
2004
Ionic mechanisms of cardiac arrhythmias
Akar F, Tomaselli G. Ionic mechanisms of cardiac arrhythmias. Drug Discovery Today Disease Mechanisms 2004, 1: 23-30. DOI: 10.1016/j.ddmec.2004.08.005.ChaptersIndividual cardiac myocytesArrhythmia controlCardiac arrhythmiasIntricate vascular networkDuke University Medical CenterCardiac myocytesGood arrhythmia controlSudden cardiac death casesCardiac death casesUniversity Medical CenterIonic mechanismsGenetic risk factorsPascal J. Goldschmidt-ClermontGlobal electrical activityCardiovascular deathAbnormal heart rhythmMalignant arrhythmiasDrug therapyRhythm disturbancesHeart diseaseRisk factorsMedical CenterTherapeutic strategiesArrhythmia syndromesCardiac chambers
2002
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank)
O’Connor C, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). The American Journal Of Cardiology 2002, 90: 101-107. PMID: 12106836, DOI: 10.1016/s0002-9149(02)02429-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac CatheterizationComorbidityCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseDisease-Free SurvivalFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedOutcome and Process Assessment, Health CareSurvival AnalysisTimeTreatment OutcomeVentricular Dysfunction, LeftConceptsCoronary artery bypass surgeryLong-term outcomesMedical therapyCoronary diseaseIschemic cardiomyopathyNew York Heart Association class IILeft ventricular ejection fractionCox proportional hazards modelDuke University Medical CenterDays of catheterizationInitial cardiac catheterizationMedical therapy armObservational treatment comparisonsCoronary artery bypassHeart failure symptomsMedical therapy groupVentricular systolic dysfunctionArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseEpicardial coronary vesselsProportional hazards modelUniversity Medical CenterCABG groupTherapy arm
1999
Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer
Havlin K, Ramirez M, Legler C, Harris L, Matulonis U, Hohneker J, Hayes D, Winer E. Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemotherapy And Pharmacology 1999, 43: 68-72. PMID: 9923543, DOI: 10.1007/s002800050864.Peer-Reviewed Original ResearchConceptsDana-Farber Cancer InstituteDuke University Medical CenterDose-limiting toxicityGrowth factor supportGrade III neurotoxicityMetastatic breast cancerFebrile neutropeniaBreast cancerFactor supportNonhematologic toxicityStarting doseDose intensityDay 4Stage IV breast cancerMajor dose-limiting toxicityAddition of filgrastimAlternative treatment regimenGrade III stomatitisGrade III vomitingGrade IV mucositisGrade IV thrombocytopeniaGreater nonhematologic toxicityPerformance status 0Prior chemotherapy regimensSemisynthetic vinca alkaloid
1994
Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Marks J, Humphrey P, Wu K, Berry D, Bandarenko N, Kerns B, Iglehart J. Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer. Annals Of Surgery 1994, 219: 332-341. PMID: 7909221, PMCID: PMC1243148, DOI: 10.1097/00000658-199404000-00002.Peer-Reviewed Original ResearchConceptsHER-2/neuEarly-stage breast cancerStage breast cancerHER-2/neu oncogeneBreast cancerPrognostic valueHER-2/neu proteinNeu oncogeneGenetic abnormalitiesDuke University Medical CenterFailure-free survivalProgesterone receptor contentCohort of patientsLimited prognostic valueIndependent prognostic valueShorter survival timeParaffin-embedded specimensUniversity Medical CenterHER-2/neu geneOverexpression of p53Common genetic abnormalityNodal statusRetrospective cohortLow estrogenTumor size
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply